Project 1

NIH Pandemic-Era Grants

Pandemic Era Grants

2021

↗ Live URL (may be dead)

Document text

Principal Investigator: Abraam M. Yakoub
Organization: UNIVERSITY OF NORTH DAKOTA
Fiscal Year: 2021
Award: $253,705
Funding agency: National Institute of General Medical Sciences

Summary
Coronavirus Disease of 2019 (COVID-19) is a US and global public health crisis. It has led to the deaths of
hundreds of thousands in the US and worldwide. COVID-19 is caused by a novel beta-coronavirus (CoV)
known as Severe Acute Respiratory Syndrome (SARS)-CoV-2, which was reported to cause severe
pneumonia and lethal respiratory failure. Little is known about the disease mechanism of this virus. Thus,
animal models are urgently needed to start to investigate the SARS-CoV-2 pathogenesis mechanisms or test
therapeutic interventions. In this application, we propose to establish the tissue tropism of SARS-CoV-2 in vivo
by comparing two different mouse models that show moderate or severe disease in parallel. We also propose
to test compound libraries to identify inhibitors of viral infection as drug candidates for COVID-19. We will also
determine how the virus modulates innate immune responses in vivo in order to establish virulence. The
proposed research will have manifold impact on the scientific battlefront on SARS-CoV-2 and the deadly
COVID-19.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><ACE2><American><Animal Model><Animal Models and Related Studies><Antiviral Agents><Antiviral Drugs><Antiviral Therapy><Antivirals><Applications Grants><Area><Basic Research><Basic Science><Biochemical><Body Tissues><COBRE><COVID-19><COVID-19 infection><COVID-19 pathogenesis><COVID-19 therapy><COVID-19 treatment><COVID-19 virus><COVID19><COVID19 infection><COVID19 pathogenesis><COVID19 therapy><COVID19 treatment><COVID19 virus><CV-19><CV19><Cell Body><Cells><Center of Biomedical Research Excellence><Centers of Research Excellence><Cessation of life><CoV-2><CoV2><Collaborations><Core Facility><Country><Death><Disasters><Disease><Disorder><Drug Therapy><Ensure><FDA approved><Faculty><Fluorescence><Foundations><Future><Genetic Models><Goals><Grant Proposals><Human><Immune><Immune response><Immunes><Immunological response><Immunomodulation><In Vitro><Individual><Infection><Inflammatory Response><Innate Immune Response><Knowledge><Libraries><Measurement><Mediating><Methods><Mice><Mice Mammals><Mission><Modern Man><Molecular><Molecular Genetics><Murine><Mus><NIH><National Institutes of Health><Outcome><Pathogenesis><Pharmacotherapy><Pneumonia><Predisposition><Public Health><R-Series Research Projects><R01 Mechanism><R01 Program><Receptor Protein><Reporter><Reporting><Research><Research Grants><Research Project Grants><Research Projects><Research Resources><Resources><Respiratory Failure><Role><SARS><SARS corona virus 2><SARS coronavirus disease><SARS-CoV disease><SARS-CoV-2><SARS-CoV-2 infection><SARS-CoV-2 pathogenesis><SARS-CoV-2 therapy><SARS-CoV-2 treatment><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome coronavirus disease><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome related corona virus 2><Severities><Susceptibility><Testing><Therapeutic Intervention><Tissues><Tropism><United States National Institutes of Health><Vaccines><Viral><Viral Diseases><Viral Pathogenesis><Virulence><Virus><Virus Diseases><Virus Inhibitors><Writing><Wuhan coronavirus><angiotensin converting enzyme 2><angiotensin converting enzyme II><animal tissue><anti-viral agents><anti-viral drugs><anti-viral therapy><anti-virals><base><beta CoV><beta coronavirus><betaCoV><betacoronavirus><block viral entry><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 pathogenesis><coronavirus disease 2019 therapy><coronavirus disease 2019 treatment><coronavirus disease 2019 virus><develop therapy><drug candidate><drug discovery><drug treatment><effective therapy><effective treatment><experience><hCoV19><host response><immune modulation><immune regulation><immune system response><immunologic reactivity control><immunomodulatory><immunoregulation><immunoregulatory><immunoresponse><in vivo><in vivo Model><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><inhibit viral entry><inhibitor><inhibitor/antagonist><insight><intervention development><intervention therapy><lung failure><model of animal><model organism><mouse model><murine model><nCoV2><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><novel><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pandemic><pandemic disease><pathogen><pulmonary failure><receptor><severe acute respiratory syndrome coronavirus 2 pathogenesis><severe acute respiratory syndrome coronavirus 2 therapy><severe acute respiratory syndrome coronavirus 2 treatment><small molecule><social role><success><synergism><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic evaluation><therapeutic testing><therapy development><tissue tropism><treat COVID-19><treat COVID19><treat SARS-CoV-2><treat coronavirus disease 2019><treat severe acute respiratory syndrome coronavirus 2><treatment development><viral entry blocker><viral entry inhibitor><viral infection><viral infectious disease treatment><viral inhibitor><virology><virus infection><virus pathogenesis><virus tropism><virus-induced disease><β CoV><β coronavirus><βCoV>